Hello everyone, great to have your company on Kalkine TV. I'm Rachael and you’re watching
Buzzing Trends. In today’s show we’ll be looking at four ASX-listed pharmacy stocks.
The Australian pharmacy retail market has been witnessing growth lately on the back of increasing
number of pharmacists, rising demographics of ageing population, healthcare challenges,
along with the number of insured patients. Furthermore, the growth in the pharmacy retail
market was supported by the increasing number of pharmacies, services, and home deliveries of
medications. The COVID-19 pandemic has highlighted the need of providing value-added services
and the presence of online pharmacies across Australia. With the growing online presence and
store expansion, major famous pharmacy retailers in the country are generating significant profit.
With this backdrop, let’s take a look at four ASX-listed pharmacy stocks.
The first company on our radar today is EBOS Group. The ASX-listed diversified
company is a wholesaler, marketer, and distributor of healthcare,
pharmaceutical and medical products across Australasia. The Company is also an animal care
brand owner, product marketer and distributor. The EBOS Group recently announced that the Company
has completed the acquisition of Australia-based Sentry Medical and expanded its business further
into medical consumables. The Company believer Sentry Medical will further bolster its presence
in the distribution of medical consumables to the institutional healthcare market,
which is a flourishing business for EBOS. EBOS has completed four acquisitions over the last year
and represents a continuation of the Company’s strategy of investing for development and growth.
The share price of EBOS Group was trading at AU$ 34.30 , during the mid-market trade this
afternoon. Moving on, ASX-listed Probiotec is a manufacturer, packer and distributor of several
prescription and over-the-counter medicines, complementary medicines, consumer health products,
as well as fast-moving consumer goods. The Company has six manufacturing facilities across Australia
and is engaged in the distribution of its products both domestically and globally. In Financial Year
2021, the Company achieved strong performance despite the COVID-19 headwinds supported by
strong revenue and earnings growth. The financial and operational highlights from the financial year
2021 are Underlying revenue rose by 12percent to $120.5 million during the period. The Company,
however, recorded Net Profit After Tax of $9.1 million, up by 17percent. Meanwhile, the Multipack
LJM acquisition has performed significantly better under Probiotec’s control. Probiotec recently
completed the acquisition of H&H packaging. The Company has declared 3 cents of the final
dividend to be paid on 8 October 2021. Probiotec anticipates that its cough, cold and flu-related
products will recover progressively in financial year 2022 and more fully in financial year 2023.
Meanwhile, Probiotec will also execute its consolidation project during financial year
2022 and 2023, with synergies starting from the beginning of financial year 2024. The company
will also focus on further acquisitions. The share price of Probiotec was trading at AU$
2.14 , during the mid-market trade this afternoon. now its time for a small break but stay tuned
on Kalkine TV
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ Hello and welcome back. Rachael this side,
we are exploring four ASX-listed pharmacy stocks. The next company on our list today
is Sigma Healthcare. ASX-listed Sigma is a leading pharmaceutical product manufacturer and marketer,
as well as the most efficient pharmaceutical wholesaler across Australia. With over
1,200 independent and branded stores, it is the largest pharmacy network across Australia.
Recently, software development and technology company, Corum disclosed the extension of its
head office suite of products with WholeLife pharmacies, Sigma Healthcare’s brands member.
For more than ten years, Corum has been providing head office software to “Discount Drug Stores”, a
Sigma group member. This extension is another step for Corum to work closely with Sigma networks.
Sigma Healthcare will release its half-year results for the period ending 31 July 2021 on
21 September 2021. The share price of Sigma Healthcare was trading at 64 cents, during
the mid-market trade this afternoon.The next company on our list is Australian Pharmaceutical
Industries. ASX-listed health and beauty player Australian Pharmaceutical Industries is the
biggest wholesale distributor of pharmaceutical as well as allied products. The Company is involved
in pharmaceutical manufacturing, distribution, and retailing. On the acquisition front,
the Australian Pharmaceutical Industries announced that the Company had obtained an indicative
non-binding proposal from Wesfarmers to acquire 100percent of the shares at a cash consideration
of AU$1.38 per share . This proposal was later rejected by the Board of Australian Pharmaceutical
Industries though. Recently, Australian Pharmaceutical Industries has received a
revised non-binding indicative proposal from Wesfarmers for the acquisition of 100percent
of the shares in Australian Pharmaceutical Industries, for cash consideration of AU$1.55 per
share. Australian Pharmaceutical Industries and Wesfarmers have entered into a Process Deed
under which Wesfarmers has been granted to undertake exclusive confirmatory due
diligence until 16 October 2021 to facilitate a binding offer. The share price of Australian
Pharmaceutical Industries was trading at AU$ 1.47, during the mid-market trade this afternoon.
With that, it’s time to wrap up today’s show. I hope you found today’s show informative - stay
tuned for more news and updates on Kalkine TV Live. This is Rachael signing off.